Clinical and epidemiologic evidence suggests that elevated levels of circulating insulin or the cleavage product of proinsulin (C-peptide) are associated with increased risk or progression of cancers of the breast (pre- and postmenopausal), endometrium, colon, kidney, and pancreas[16,17]. This evidence concerns the gene INS and cancer.